First-line serplulimab for advanced squamous non-small cell lung cancer: A multicenter, single-arm, real-world ASTRUM 004R study

被引：0
|
作者：
Shen, B. [1 ,2 ,3 ]
Yu, Z. [4 ]
Ding, H. [5 ]
Wang, H. [6 ]
Li, J. [7 ]
Xu, X. [8 ]
Tian, G. [9 ]
Han, G. [10 ]
Yin, L. [11 ]
Ji, Y. [12 ]
Zhou, Z. [13 ]
Zhou, L. [14 ]
Zhang, X. [15 ]
Sun, C. [16 ]
Ding, N. [17 ]
机构：
[1] Nanjing Med Univ, Jiangsu Canc Hosp, Med Oncol Dept, Nanjing, Peoples R China
[2] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing, Peoples R China
[3] Nanjing Med Univ, Canc Hosp, Nanjing, Peoples R China
[4] Cent S Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China
[5] First Peoples Hosp Zhenjiang, Dept Respirat, Zhenjiang, Peoples R China
[6] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Oncol, Beijing, Peoples R China
[7] Wuhu Second Peoples Hosp, Dept Resp Med, Wuhu, Peoples R China
[8] Linyi Peoples Hosp, Dept Resp Med, Linyi, Peoples R China
[9] Jining Med Coll, Affiliated Hosp, Dept Resp Med, Jining, Peoples R China
[10] Taizhou Peoples Hosp, Dept Med Oncol, Taizhou, Peoples R China
[11] Dalian Med Univ, Affiliated Hosp 1, Dept Med Oncol, Dalian, Peoples R China
[12] Anyang Canc Hosp, Dept Internal Med, Anyang, South Korea
[13] First Peoples Hosp Yancheng, Dept Respirat, Yancheng, Peoples R China
[14] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Resp Med, Nanjing, Peoples R China
[15] Qingdao Cent Hosp, Dept Stereotact Radiotherapy, Qingdao 266000, Peoples R China
[16] Yangzhou Univ, Canc Inst, Northern Jiangsu Peoples Hosp, Coll Med, Yangzhou 255000, Jiangsu, Peoples R China
[17] Wuxi Huishan Dist Peoples Hosp, Oncol Dept, Wuxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.715
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
682P
引用
收藏
页码：S1660 / S1660
页数：1
相关论文
共 50 条
  • [41] The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer
    Liu, Lei
    Li, Fuxia
    Zhao, Jing
    Zhuo, Xiaoli
    Lai, Jingjiang
    Wang, Jingliang
    Jiang, Fengxian
    Xu, Wei
    Luan, Fang
    Lin, Xiaoyan
    Yang, Shuping
    Fu, Guobin
    JOURNAL OF CANCER, 2023, 14 (06): : 952 - 965
  • [42] Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer
    Xing, Puyuan
    Mu, Yuxin
    Wang, Yan
    Hao, Xuezhi
    Zhu, Yixiang
    Hu, Xingsheng
    Wang, Hongyu
    Liu, Peng
    Lin, Lin
    Wang, Zhijie
    Li, Junling
    THORACIC CANCER, 2018, 9 (07) : 805 - 813
  • [43] Real-world survival with first-line (1L) chemotherapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)
    Waterhouse, D.
    Betts, K. A.
    Zhao, J.
    Rao, S.
    Gupte-Singh, K.
    Rutstein, M.
    Higashi, M. K.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 29 - U99
  • [44] Bevacizumab combined with pemetrexed plus cisplatin followed by maintenance bevacizumab/pemetrexed as first-line treatment of advanced non-squamous non-small cell lung cancer: A single-arm Phase 2 study
    Santoro, Armando
    Hillerdal, Gunnar N.
    Hoeffkenc, Gert
    Favaretto, Adolfo
    Carrion, Ramon Perez
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Helsberg, Karin
    Soldatenkova, Victoria
    Bourayou, Nawel
    Sorensen, Jens B.
    LUNG CANCER, 2014, 86 (01) : 47 - 53
  • [45] First-line treatment patterns and outcomes in advanced non-small cell lung cancer in Sweden: a population-based real-world study with focus on immunotherapy
    Wagenius, Gunnar
    Vikstrom, Anders
    Berglund, Anders
    Salomonsson, Stina
    Bencina, Goran
    Hu, Xiaohan
    Chirovsky, Diana
    Brunnstrom, Hans
    ACTA ONCOLOGICA, 2024, 63 : 198 - 205
  • [46] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [47] Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
    Li, Hongxin
    Zhao, Wen
    Chang, Caiyun
    Xuan, Tiantian
    Wang, Chengjun
    Zhang, Rongyu
    Yang, Chuang
    Wang, Jian
    Yi, Cuihua
    Wang, Xiuwen
    Yu, Shuwen
    Li, Jisheng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [48] Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 positive expression: A multicenter, single-arm phase 2 study
    Cheng, Ying
    Shen, Lin
    Chen, Zhendong
    Ye, Feng
    Yu, Xianjun
    Zhang, Xing
    Ji, Dongmei
    Liu, Baorui
    Song, Lijie
    Wu, Chunjiao
    Lu, Ming
    Chen, Wei
    Wu, Jingxun
    Gao, Heli
    Weng, Desheng
    Shen, Weina
    Li, Rutian
    Yang, Minjie
    Zhou, Jinghong
    Shi, Haiyan
    Tan, Panfeng
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    CANCER RESEARCH, 2023, 83 (08)
  • [49] Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam
    Pham, C. T. M.
    Hoang, T. T. A.
    Truong, P. T.
    Bui, P. T. T.
    Nguyen, T. T.
    Vo, T. N.
    Tran, D. T.
    Nguyen, D. T.
    Tran, T. X.
    Le, H. H.
    Dong, H. Q.
    Nguyen, K. T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S662 - S663
  • [50] A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
    Yoon, S. H.
    Kim, Y. S.
    Chung, J. H.
    Seol, H. Y.
    Kim, M. H.
    ANNALS OF ONCOLOGY, 2019, 30
12345